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Abstract
Background: A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted 
an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us 
to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we 
have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of 
M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection 
against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the 
H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 
2009 H1N1 virus.
Results: Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-
reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation 
with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly 
to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could 
afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of 
viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% 
of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal 
challenge with pandemic H1N1 virus.
Conclusions: Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence 
of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with 
the 2009 swine-origin H1N1 influenza virus.
Background
At the same time concern was raised about a possible
pandemic resulting from the highly pathogenic avian
influenza (HPAI) H5N1 virus, the world confronted the
first influenza pandemic of the 21st century caused by a
novel influenza A H1N1 virus [1]. This pandemic H1N1
virus was first identified in April 2009 and demonstrated
a rapid rate of spread. As of 9 May, 2010, WHO has
reported at least 18,036 fatal cases in more than 214
countries [2]. Although H5N1 virus has not yet evolved to
become transmissible among humans, it has still pre-
sented a high mortality rate of approximately 60% [3].
Consequently, WHO considers the H5N1 virus to be a
potential human pandemic [4]. Antigenic and genetic
analysis has suggested that the current pandemic 2009
H1N1 virus is a product of reassortment between genes
in the human, avian and swine influenza strains [5].
There is a concern that one more human pandemic influ-
enza virus could be derived in the future from animal res-
ervoirs, such as avian, possessing both rapid
interpersonal transmissibility and high lethality. The
potential shortage of pandemic influenza vaccines and
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Page 2 of 6the absence of specific-immunity in the human popula-
tion make the development of a cross-protective influ-
enza vaccine, which is based on conserved antigens, a
promising prophylactic strategy.
The extracellular domain of influenza M2 protein
(M2e) is highly conserved across influenza A subtypes
and has become an attractive antigen target for produc-
ing a cross-protective influenza vaccine with broad-
spectrum prevention [6]. To date, many groups have
reported M2e-based vaccine candidates in different
forms such as virus-like particles [7-9], recombinant
proteins [10-12], DNA [13], and synthetic peptides
[14,15]. However, most of these M2e vaccines require
either chemical or genetic strategies to form M2e-car-
rier fusion constructs in order to overcome the poor
immunogenicity of M2e alone. Therefore, multiple anti-
genic peptides (MAPs) would provide an ideal platform
for the application of a vaccine based on a short peptide
antigen, such as M2e. This type of construct would
result in a large macromolecule with a high molar ratio
of target peptide antigen to a small immunologically
inert core molecule without requiring further conjuga-
tion to a carrier protein [16,17]. In our previous study,
we designed and synthesized a MAP with radially
branching lysine dendrites onto which four copies of
conserved M2e of H5N1 virus were attached. Such
H5N1-M2e-MAP vaccine elicited high titers of H5N1-
M2e-specific serum antibodies and conferred effica-
cious protection against different clades of H5N1 virus
[18]. Here, we further proved that the H5N1-M2e-MAP
candidate vaccine can provide heterosubtypic protec-
tion against lethal infection of pandemic 2009 H1N1
virus.
Materials and methods
Mice
Six- to eight-week-old female BALB/c mice were pur-
chased from the Beijing Animal Center (Beijing, China).
All mice were maintained in a specific pathogen-free
facility and housed in cages containing sterilized feed,
autoclaved bedding and water. The animal study was
approved by the Institutional Animal Care and Use Com-
mittee (IACUC).
Virus
The pandemic 2009 H1N1 virus used in this study is A/
Beijing/501/09 isolated from a confirmed H1N1 case in
China. Virus was grown in the allantoic cavities of 10-
day-old embryonated chicken eggs. Virus-containing
allantoic fluid was harvested and stored in aliquots at -
80°C until use. The 50% lethal dose (LD50) was deter-
mined in mice after serial dilutions of the virus stock. All
infectious experiments were performed in an approved
biosafety level 3 (BSL-3) facility.
H5N1-M2e-MAP
As described previously [18], tetra-branched multiple
antigenic peptide carrying four copies of M2e peptide of
H5N1 virus (H5N1-M2e-MAP) was synthesized on
[Fmoc-Lys(Fmoc)]2-Lys-Cys(Acm)-βAla-Wang Resin
(Advanced ChemTech, Louisville, Kentucky, USA) on a
0.02 mM scale using an Applied Biosystems model 433A
peptide synthesizer. Cleavage of the peptide from the
resin was performed by treatment with trifluoroacetic
acid (TFA), DTT, water, and triisopropylsilane (TIPS) in
the ratio 88:5:5:2 (TFA/DTT/H2O/TIPS). Crude peptide
was purified by reversed phase high-performance liquid
chromatography (RP-HPLC). The structure of H5N1-
M2e-MAP is shown in Fig. 1.
Immunization and virus challenge
Mice were vaccinated subcutaneously (s.c.) with 10 μg of
H5N1-M2e-MAP in the presence of Freund's complete
adjuvant (Sigma, MO) or intramuscularly (i.m.) plus alu-
minum adjuvant (Sigma). The 1st boost was given with
the same amount of H5N1-M2e-MAP in Freund's incom-
plete adjuvant (Sigma) or aluminum adjuvant three weeks
later. The mice received the 2nd boost six months later.
Mice injected with Freund's or aluminum adjuvant alone
were used as the respective control. Sera were collected at
1 week and 3 and 6 months after 1st boost and 1 week
after 2nd boost to detect cross-reactive antibodies against
H1N1-M2e. Sera collected before immunization were
used as negative controls. Two weeks after 2nd boost,
mice were intraperitoneally (i.p.) anesthetized with ket-
amine (75 mg/kg) and intranasally (i.n.) challenged with a
lethal dose (10LD50) of A/Beijing/501/09. Infected mice
were observed and weighed daily for 2 weeks. Lung tis-
sues were collected from euthanized mice 3 days post-
challenge for further virological testing and histopatho-
logical analysis.
Figure 1 Structure of the synthetic H5N1-M2e-MAP. The M2e-MAP 
was synthesized on [Fmoc-Lys(Fmoc)]2-Lys-Cys(Acm)-βAla-Wang Res-
in in a tetra-branched form, which carries four copies of H5N1-M2e. 
The amino acid sequences of H5N1-M2e derived from A/Vietnam/
1194/04(H5N1) and the H1N1-M2e sequence from A/Beijing/501/
09(H1N1) are respectively listed at the bottom of this figure. The differ-
ence between H1N1-M2e and H5N1-M2e is bolded and underlined.
H5N1-M2e 
Lys 
Lys
Lys Cys(Acm) Ala 
H5N1-M2e 
H5N1-M2e 
H5N1-M2e 
H5N1-M2e [A/Vietnam/1194/04(H5N1)]: MSLLTEVETPTRNEWECRCSDSSD 
H1N1-M2e [A/Beijing/501/09(H1N1)]:    MSLLTEVETPTRSEWECRCSDSSD 
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The cross-reactivity of H5N1-M2e-MAP-induced anti-
body against H1N1-M2e was detected by ELISA. Briefly,
96-well microtiter plates were pre-coated with 10 μg/ml
of H1N1-M2e peptide (SBS Genetech, Beijing, China)
overnight at 4°C. After blocking with 5% BSA containing
0.05% Tween-20 in PBS, serial diluted mouse sera were
added to the plates, followed by addition of HRP-conju-
gated rabbit anti-mouse IgG (1:2,000, Invitrogen, Carls-
bad, CA) at 37°C for 0.5 h. Assay was developed using
3,3',5,5'-tetramethylbenzidine (TMB) (Zymed, Carlsbad,
CA), and the reaction was stopped by adding 1N H2SO4.
The absorbance at 450 nm was measured by an ELISA
plate reader (Sunrise™ microplate reader, TECAN, NC).
Viral titers in lung tissues
Viral titers in lungs were determined by 50% Tissue cul-
ture infective dose (TCID50) as described [18], except that
TPCK-trypsin (Sigma) was added into the medium (2 μg/
ml), and 0.5% chicken erythrocytes were used in hemag-
glutination confirming cytopathic effect (CPE) endpoint.
Histopathological analysis
The lung tissues of challenged mice were immediately
fixed in 10% neutral buffered formalin and embedded in
paraffin wax. Sections were made at 4 - 6 μm thickness
and mounted on slides. Histopathological changes were
examined by H & E staining and observed under light
microscopy.
Statistical analysis
The significance between survival curves was analyzed by
Kaplan-Meier survival analysis with log-rank test. Other
data were analyzed using the 2-tailed Student's t test. P <
0.001 was considered significant. All analyses were per-
formed in Graphpad Prism software.
Results
H5N1-M2e-MAP vaccination induced high titers of cross-
reactive antibody against H1N1-M2e peptide
The M2e of human influenza virus is significantly differ-
ent from that of avian influenza virus [19]. However, the
pandemic 2009 H1N1 virus and H5N1 virus share a simi-
lar M2e sequence, except for one amino acid, as indicated
in Fig. 1 with representative virus stains. The serological
examination illustrated the cross-reactivity of H5N1-
M2e-MAP-induced antibodies that recognized H1N1-
M2e. As shown in Fig. 2, one week after the 1st boost,
H5N1-M2e-MAP in Freund's adjuvant or aluminum
adjuvant elicited strong cross-reactive IgG antibody
against H1N1-M2e with the titer reaching 1:105 or 1:104,
respectively. Despite a slight decrease in the following six
months, the titers of cross-reactive antibody bounced
back quickly to the previous high level after the 2nd boost.
In contrast, only background level of anti-H1N1-M2e
antibody response was detected in Freund's or aluminum
adjuvant controls. These results suggest that H5N1-M2e-
MAP can induce long-term and potent antibody
responses that may be effective against both homologous
HPAI H5N1 virus and heterologous pandemic 2009
H1N1 virus.
H5N1-M2e-MAP vaccination limited replication of 
pandemic 2009 H1N1 and attenuated virus-induced lung 
pathology
In our established mouse model, the virus replicated in
the lung tissue to the peak, reaching the highest titer
three days post-lethal infection of pandemic 2009 H1N1
virus (data not shown). To determine whether the H5N1-
M2e-MAP-induced immune responses confer heterosub-
typic protection against infection with pandemic 2009
H1N1 virus, the vaccinated mice were sacrificed three
days after lethal virus challenge (10LD50) of A/Beijing/
501/09 and lung tissues were collected for detection of
viral titers and histopathological examination. Compared
with the matched adjuvant control group, the average
viral titer in lungs of H5N1-M2e-MAP-vaccinated mice
was significantly lower (P < 0.001) after lethal challenge
with the pandemic 2009 H1N1 virus (Fig. 3A), suggesting
that the H5N1-M2e-MAP can induce potent protective
immunity against viral replication following pandemic
2009 H1N1 virus infection.
Further examination of the lung tissues of virus-chal-
lenged mice revealed that dramatic lung damages mainly
occurred in the control mice, which were characterized
by diffused alveolar lesion with pneumocytes denatured,
alveolar macrophages and cellular debris mixed with
Figure 2 Cross-reactivity of H5N1-M2e-MAP-induced antibody 
against H1N1-M2e peptide. Mice were primed and boosted with 
H5N1-M2e-MAP vaccine and sera were collected as described in Mate-
rials and Methods to detect cross-reactivity against H1N1-M2e by ELI-
SA. The end-point titer of each sample was determined as the highest 
dilution that yielded an OD450 nm value greater than twice of that from 
pre-vaccination. The data are expressed as mean ± standard deviation 
(SD) of 10 mice per group. The lower limit of detection (1:20) is indicat-
ed by a dotted line. Time points of immunizations are shown as small 
spots on X-axis, and indicated by arrows at the bottom.
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Page 4 of 6fibrin in alveolar lumina, and widened lung septa with the
infiltration of lymphocytes and a few neutrophils. The
bronchiolar epithelium was degenerated and collapsed
with multifocal peribronchiolar infiltration of lympho-
cytes and a few neutrophils. The blood vessel endothe-
lium was damaged with moderate edema and infiltration
of lymphocytes and neutrophils in the periendothelium.
However, lungs of H5N1-M2e-MAP-vaccinated mice
exhibited fewer histopathological changes, with only mild
pulmonary interstitial pneumonia and moderate lympho-
cytic infiltration (Fig. 3B). The above data implied that
H5N1-M2e-MAP vaccination protects mice against
lethal infection with the pandemic 2009 H1N1 virus
through a combination of limiting viral replication in the
lungs and attenuating virus-induced lung pathology.
H5N1-M2e-MAP vaccination provided effective 
heterosubtypic protection from lethal challenge with 
pandemic 2009 H1N1 virus
To further confirm cross-protection conferred by H5N1-
M2e-MAP against heterologous infection with the pan-
demic 2009 H1N1 virus, mice received lethal challenge
(10LD50) of A/Beijing/501/09 strain were monitored for
weight loss and death for the subsequent two weeks post-
challenge. As shown in Fig. 4A, mice vaccinated with
H5N1-M2e-MAP in Freund's or aluminum adjuvant ral-
lied from body weight loss eight days after virus infection.
In contrast, body weight of the mice in the adjuvant con-
trol group dramatically decreased, even more than 25%,
in some cases. All mice received adjuvant alone died
within 10 days after lethal virus challenge. In comparison,
100% and 80% of the mice survived in the groups vacci-
nated with H5N1-M2e-MAP in Freund's and aluminum
adjuvants, respectively, with the survival rate significantly
different from the matched adjuvant control (P < 0.001)
Figure 4 Cross-protection of H5N1-M2e-MAP-vaccinated mice 
against lethal challenge of pandemic 2009 H1N1 virus. H5N1-
M2e-MAP-vaccinated mice were challenged with lethal dose (10LD50) 
of heterosubtypic H1N1 virus A/Beijing/501/09 strain and monitored 
daily for 2 weeks post-challenge. (A) Percentage change (%) of mouse 
body weight. Each point represents mean body weight of 10 mice per 
group. (B) Survival rate (%). The significant differences (P < 0.001) of 
H5N1-M2e-MAP plus Freund's adjuvant versus Freund's adjuvant is in-
dicated as *, while H5N1-M2e-MAP plus aluminum adjuvant versus 
aluminum adjuvant is indicated as **.
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Figure 3 Detection of viral titers and histopathological changes 
in lungs of the H5N1-M2e-MAP-vaccinated mice following het-
erosubtypic challenge with pandemic 2009 H1N1 virus. Two 
weeks post-last boost, H5N1-M2e-MAP-vaccinated mice were chal-
lenged with lethal dose (10LD50) of pandemic 2009 H1N1 virus A/Bei-
jing/501/09 strain, and lung tissues were collected three days later. (A) 
Viral titers in lungs of infected mice. The data are expressed as 
Log10TCID50/g of lung tissues, and presented as GMT ± SD of 5 mice 
per group. * indicates P < 0.001 compared to the Freund's adjuvant 
control; ** means P < 0.001 compared to the aluminum adjuvant con-
trol. Experiments were repeated three times. (B) Histopathological 
changes in the lungs following virus challenge. The figure indicates the 
representative images of histopathological damage from H & E-stained 
lungs of 5 mice per group (magnification, 100×).
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Page 5 of 6(Fig. 4B). These data illustrated that H5N1-M2e-MAP
can afford heterosubtypic protection against lethal chal-
lenge of pandemic 2009 H1N1 virus.
Discussion
To develop safe and effective prophylactic strategies to
combat human infections by both pandemic 2009 H1N1
virus and H5N1 virus, the highly conserved M2e of influ-
enza A virus has proven to be a promising target antigen
to produce cross-protective influenza vaccines. In this
study, H5N1-M2e-MAP, whose cross-protection against
different clades of H5N1 virus has already been estab-
lished in our previous report [18], was shown to confer
heterosubtypic protection from lethal infection with the
pandemic 2009 H1N1 virus. Remarkably, all mice vacci-
nated with H5N1-M2e-MAP plus Freund's adjuvant sur-
vived the lethal heterologous virus challenge. Although
there is partial protection (80%) in the H5N1-M2e-MAP
plus aluminum adjuvant group, H5N1-M2e-MAP vacci-
nation in both Freund's and aluminum adjuvants demon-
strated similar efficacy in limiting viral replication and
attenuating virus-producing histopathological damage in
lung tissues, thus showing the ability to control disease
transmission.
Notably, it seems that higher titers of cross-reactive
antibodies against H1N1-M2e result in better heterosub-
typic protection from lethal virus infection (Figs. 2 and 4),
implying that M2e-induced cross-reactive antibody is a
crucial component in heterosubtypic protection in M2e-
based vaccines. Other groups have reported that the anti-
viral effect of M2e-based vaccines was mediated by anti-
bodies to M2e antigen and that its mechanism was
antibody-dependent cell-mediated cytotoxicity (ADCC)
and/or complement-mediated cytotoxicity (CDC)
[20,21]. Therefore, the cross-protection of the M2e vac-
cine was based on the premise that antibody responses
with high levels of cross-reactivity were induced follow-
ing vaccination. However, the difference of M2e amino
acid sequences between human-type and avian-type
viruses would affect their mutual recognition in varying
degrees. Specifically, Fan et al. [14] reported that antisera
against human-type M2e sequence failed to react with
avian-type M2e peptide. Also, Liu et al. [22] indicated
that mAb specific to a region (aa 6 - 13) of human-type
M2e sequence can only weakly recognize, or not recog-
nize at all, avian-type M2e sequence with variations in
the same range. Nevertheless, in our studies, H5N1-M2e-
MAP not only induced high titers of specific antibody
against H5N1-M2e [18] but also elicited potent and pro-
longed cross-reactive antibody recognizing H1N1-M2e
(Fig. 2). Although it is not certain whether the only amino
acid difference between the H1N1-M2e and H5N1-M2e
(as indicated in Fig. 1) is located outside the region con-
taining B-cell epitopes, the induction of cross-reactive
antibody by H5N1-M2e-MAP against H1N1-M2e is
obvious, and it is confirmed that H5N1-M2e-MAP can
afford heterosubtypic protection against pandemic 2009
H1N1 virus (Figs. 3 and 4), regardless of the difference in
M2e sequence between H1N1 and H5Nl by one amino
acid.
Given that the immunization regimen consisting of
H5N1-M2e-MAP and aluminum, the only adjuvant
approved for use in humans, induced weaker immune
responses (Fig. 2) and protective immunity (Fig. 4) than
that is comprised of H5N1-M2e-MAP and Freund's adju-
vant, it is urgently needed to develop more effective and
safe adjuvant than aluminum for clinical use of human
vaccines.
Conclusions
The highly conserved M2e is an appropriate antigen tar-
get for the development of a cross-protective influenza
vaccine. The present study revealed that the H5N1-M2e-
MAP vaccine, whose cross-clade protection against
divergent H5N1 viruses was confirmed in our previous
report, can afford heterosubtypic protection against pan-
demic 2009 H1N1 virus, supporting the concept of an
M2e-based vaccine with broad-spectrum protection
against both the existing influenza virus and the emer-
gent variant.
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